Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

Table 1

Population characteristic.

Population characteristic	N (%)
PATIENTS	61
Age, y, range (median)	66 (41-88)
Male	51 (84)
Female	10 (16)
Smokers	47 (77)
Non-smoking	14 (23)
Clinical staging
Ta	28 (46)
T1	18 (30)
T2	4 (6)
T3	5 (8)
TIS	6 (10)
Clinical grading
LG	29 (53)
HG	32 (47)
Clinical subgroups
NMIBC	46 (75)
MIBC	15 (25)
CONTROLS	33
Age, y, range (median)	65 (54-81)
Male	28 (85)
Female	5 (15)
Smokers	24 (73)
Nonsmokers	9 (27)

Ta, T1, T2, TIS: subgroups, according to tumor stage T (TNM: Tumor Nodules Metastases, 2002r.); NMIBC: non-muscle invasive BC; MIBC: muscle invasive BC; LG: low grade; HG: high grade; n: number of cases; y: years.